trial · primary record
Tobevibart
Viral Hepatitis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 124 |
| Primary completion | 2031-05 |
| Primary endpoint | HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2 |
| Registry ID | NCT06903338 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:55.521Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06903338
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.